Nektar Therapeutics (NKTR)
1.38
-0.04
(-2.82%)
USD |
NASDAQ |
Apr 24, 16:00
1.39
+0.01
(+0.72%)
After-Hours: 20:00
Nektar Therapeutics Research and Development Expense (Quarterly): 29.94M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 29.94M |
| September 30, 2023 | 24.07M |
| June 30, 2023 | 29.68M |
| March 31, 2023 | 30.47M |
| December 31, 2022 | 34.74M |
| September 30, 2022 | 33.59M |
| June 30, 2022 | 42.74M |
| March 31, 2022 | 107.25M |
| December 31, 2021 | 99.61M |
| September 30, 2021 | 103.74M |
| June 30, 2021 | 101.31M |
| March 31, 2021 | 95.60M |
| December 31, 2020 | 102.72M |
| September 30, 2020 | 100.53M |
| June 30, 2020 | 96.44M |
| March 31, 2020 | 108.99M |
| December 31, 2019 | 110.37M |
| September 30, 2019 | 99.05M |
| June 30, 2019 | 106.69M |
| March 31, 2019 | 118.46M |
| December 31, 2018 | 108.88M |
| September 30, 2018 | 102.90M |
| June 30, 2018 | 88.33M |
| March 31, 2018 | 99.42M |
| December 31, 2017 | 81.43M |
| Date | Value |
|---|---|
| September 30, 2017 | 65.71M |
| June 30, 2017 | 60.26M |
| March 31, 2017 | 61.06M |
| December 31, 2016 | 50.23M |
| September 30, 2016 | 51.95M |
| June 30, 2016 | 52.35M |
| March 31, 2016 | 49.27M |
| December 31, 2015 | 47.14M |
| September 30, 2015 | 43.23M |
| June 30, 2015 | 45.41M |
| March 31, 2015 | 47.01M |
| December 31, 2014 | 38.49M |
| September 30, 2014 | 34.20M |
| June 30, 2014 | 36.70M |
| March 31, 2014 | 38.34M |
| December 31, 2013 | 48.25M |
| September 30, 2013 | 43.91M |
| June 30, 2013 | 52.23M |
| March 31, 2013 | 45.62M |
| December 31, 2012 | 46.37M |
| September 30, 2012 | 34.02M |
| June 30, 2012 | 33.20M |
| March 31, 2012 | 35.08M |
| December 31, 2011 | 33.30M |
| September 30, 2011 | 31.02M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
24.07M
Minimum
Sep 2023
110.37M
Maximum
Dec 2019
76.71M
Average
99.05M
Median
Sep 2019
Research and Development Expense (Quarterly) Benchmarks
| Stereotaxis Inc | 2.212M |
| Vanda Pharmaceuticals Inc | 24.34M |
| Cara Therapeutics Inc | 28.42M |
| Marinus Pharmaceuticals Inc | 26.38M |
| DiaMedica Therapeutics Inc | 3.677M |